CureVac Shares Rise 24% on Covid-19, Flu Vaccine Clinical Data
By Denny Jacob CureVac NV shares rose 24%, to $7.94, on Friday after the company said its Covid-19 and flu vaccine candidates are advancing to the next stage of testing following the release of their clinical program data.…